Rocket Pharmaceuticals, Inc. Cash Acquired from Acquisition
Rocket Pharmaceuticals, Inc. (RCKT) reported Cash Acquired from Acquisition of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Cash
us-gaap:CashAcquiredFromAcquisition · last filed 2025-02-27
- Rocket Pharmaceuticals, Inc. cash acquired from acquisition for the quarter ending 2019-12-31 was $0.00.
- Rocket Pharmaceuticals, Inc. cash acquired from acquisition for the quarter ending 2019-09-30 was $0.00.
- Rocket Pharmaceuticals, Inc. cash acquired from acquisition for the quarter ending 2019-06-30 was $0.00.
- Rocket Pharmaceuticals, Inc. cash acquired from acquisition for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. cash acquired from acquisition for fiscal 2024 was $0.00.
- Rocket Pharmaceuticals, Inc. cash acquired from acquisition for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Rocket Pharmaceuticals, Inc. cash acquired from acquisition for fiscal 2022 was $42.73M.
- Rocket Pharmaceuticals, Inc. cash acquired from acquisition for fiscal 2021 was $0.00.
| Period end | Cash Acquired from Acquisition 3 month | Cash Acquired from Acquisition 6 month | Cash Acquired from Acquisition 9 month | Cash Acquired from Acquisition 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $42.73M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $0.00 10-Q · filed 2019-11-08 | $0.00 derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $76.35M 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $76.35M 10-Q · filed 2019-11-08 | $76.35M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $76.35M 10-Q · filed 2019-08-08 | $76.35M derived: sum of 3 quarters · filed 2019-08-08 | $76.35M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $76.35M 10-Q · filed 2019-05-09 | $76.35M derived: sum of 2 quarters · filed 2019-05-09 | $76.35M derived: sum of 3 quarters · filed 2019-05-09 | $76.35M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $0.00 derived: sum of 2 quarters · filed 2019-03-08 | $0.00 derived: sum of 3 quarters · filed 2019-03-08 | $0.00 10-K · filed 2019-03-08 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |